Expertise in
12
conditions

Bjorn Eliasson

Goeteborg, O, SE 
Expertise in
12
conditions
Goeteborg, O, SE 

Overview

Bjorn Eliasson practices practicing medicine in Goeteborg, Sweden.

Dr. Eliasson is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), Maturity Onset Diabetes of the Young, Gastric Bypass, and Coronary Artery Bypass Graft (CABG).

He is actively involved in clinical research, co-authoring 247 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Goeteborg, O, Sweden
Other Locations
Sweden
Uppsala, C, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
An Open, Single-arm, Multi Centre Pilot Investigation to Evaluate the Debriding Effect of ChloraSolv® on Chronic Wounds, Covered With Devitalised Tissue, During Six Weeks Treatment
An Open, Single-arm, Multi Centre Pilot Investigation to Evaluate the Debriding Effect of ChloraSolv® on Chronic Wounds, Covered With Devitalised Tissue, During Six Weeks Treatment
Enrollment Status: Completed
Publish Date: April 08, 2021
Intervention Type: Device
Study Phase: Not Applicable
View 1 Less Clinical Trial

247 Total Publications

Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy : A Nationwide Cohort Study.
Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy : A Nationwide Cohort Study.
Journal: Annals of internal medicine
Published: July 13, 2026

Frequently Asked Questions about Bjorn Eliasson

Is Bjorn Eliasson a top-rated expert for Type 2 Diabetes (T2D)?

MediFind is an objective health platform that identifies experts based on real-world data. Bjorn Eliasson is classified as an Elite expert for Type 2 Diabetes (T2D), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Bjorn Eliasson participate in research or clinical trials?

Yes. Bjorn Eliasson has published 247 articles and abstracts on conditions like Type 2 Diabetes (T2D). You can view a list of Bjorn Eliasson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Eliasson's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile